EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS‐CoV‐2 mRNA vaccine

Cinzia Borgogna iD, Daniela Ferrante iD, Greta Rosso, Gabriele Guglielmetti, Irene Lo Cigno iD, Stefano Raviola iD, Valeria Caneparo iD, Marco Quaglia iD, Vincenzo Cantaluppi iD, Marisa Gariglio iD

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29710 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Cinzia Borgogna und 9 weiteren Autor:innen. Beteiligte Einrichtung: Virology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Hauptthemen laut MEDLINE: Kidney Transplantation, Antibodies, Viral, Antibodies, Neutralizing, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regione Piemonte, Chiesi Farmaceutici, Università degli Studi del Piemonte Orientale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney transplant recipients (KTRs), like other solid organ transplant recipients display a suboptimal response to mRNA vaccines, with only about half achieving seroconversion after two doses. However, the effectiveness of a booster dose, particularly in generating neutralizing antibodies (NAbs), remains poorly understood, as most studies have mainly focused on non‐neutralizing antibodies. Here, we have longitudinally assessed the humoral response to the SARS‐CoV‐2 mRNA vaccine in 40 KTRs over a year, examining changes in both anti‐spike IgG and NAbs following a booster dose administered about 5 months post‐second dose. We found a significant humoral response increase 5 months post‐booster, a stark contrast to the attenuated response observed after the second dose. Of note, nearly a quarter of participants did not achieve protective plasma levels even after the booster dose. We also found that the higher estimated glomerular filtration rate (eGFR) correlated with a more robust humoral response postvaccination. Altogether, these findings underscore the effectiveness of the booster dose in enhancing durable humoral immunity in KTRs, as evidenced by the protective level of NAbs found in 65% of the patients 5 months post‐ booster, especially those with higher eGFR rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationAntibodies, ViralAntibodies, NeutralizingCOVID-19Immunity, HumoralSARS-CoV-2Immunization, SecondaryTransplant RecipientsCOVID-19 VaccinesHumansMaleFemaleMiddle AgedProspective StudiesAgedAdultImmunoglobulin GMonitoring, ImmunologicmRNA VaccinesSpike Glycoprotein, CoronavirusLongitudinal Studies

Stichwörter der Autor:innen

SARS‐CoV‐2booster vaccinationestimated glomerular filtration rate (eGFR)kidney transplant recipients (KTRs)neutralizing antibodies

Substanzen

Antibodies, ViralAntibodies, NeutralizingCOVID-19 VaccinesImmunoglobulin GmRNA VaccinesSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Virology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Medical Statistics, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Nephrology and Kidney Transplantation Unit, Department of Translational Medicine, "Maggiore della Carità" University Hospital, University of Piemonte Orientale, Novara, Italy.
  • Intrinsic Immunity Unit, Department of Translational Medicine, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, University of Piemonte Orientale, Novara, Italy.
  • Nephrology and Dialysis Unit, Department of Translational Medicine, "SS Biagio e Cesare" University Hospital, University of Piemonte Orientale, Alessandria, Italy.

ORCID-Profile: Cinzia Borgogna, Daniela Ferrante, Irene Lo Cigno, Stefano Raviola, Valeria Caneparo, Marco Quaglia, Vincenzo Cantaluppi, Marisa Gariglio

Förderung

  • Regione Piemonte
  • Chiesi Farmaceutici
  • Università degli Studi del Piemonte Orientale
  • Ministero dell'Università e della Ricerca

Zitieren

APA

Borgogna, C., Ferrante, D., Rosso, G., Guglielmetti, G., Lo Cigno, I., Raviola, S., Caneparo, V., Quaglia, M., Cantaluppi, V., & Gariglio, M. (2024). A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS‐CoV‐2 mRNA vaccine. Journal of Medical Virology. https://doi.org/10.1002/jmv.29710

Vancouver

Borgogna C, Ferrante D, Rosso G, Guglielmetti G, Lo Cigno I, Raviola S, et al. A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS‐CoV‐2 mRNA vaccine. Journal of Medical Virology. 2024. doi:10.1002/jmv.29710

BibTeX
@article{Borgogna2024,
  author = {Borgogna, Cinzia and Ferrante, Daniela and Rosso, Greta and Guglielmetti, Gabriele and Lo Cigno, Irene and Raviola, Stefano and Caneparo, Valeria and Quaglia, Marco and Cantaluppi, Vincenzo and Gariglio, Marisa},
  title = {A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS‐CoV‐2 mRNA vaccine},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29710}
}
Kostenlos starten →